Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4926471 | 0.97 | POLB (0.45) | POLBTRPV1MAPK1ALDH1A1HTT | |
| SCHEMBL5402993 | 0.94 | MAPK1 (0.44) | TRPV1MAPK1ALDH1A1HTTNPSR1 | |
| SCHEMBL4928569 | 0.87 | TRPV1 (0.46) | POLBTRPV1MAPK1ALDH1A1LMNA | |
| SCHEMBL5395614 | 0.86 | LTB4R (0.41) | POLBTRPV1ALDH1A1NOTUM | |
| SCHEMBL5394588 | 0.86 | POLB (0.43) | POLBALDH1A1RAF1MAP2K1LMNA | |
| SCHEMBL4930242 | 0.86 | POLB (0.49) | POLBALDH1A1HTTNPSR1LMNA | |
| SCHEMBL5394305 | 0.85 | NOTUM (0.43) | TRPV1ALDH1A1HTTLMNAKMT2A | |
| SCHEMBL5412105 | 0.85 | TRPV1 (0.46) | TRPV1ALDH1A1KMT2A | |
| SCHEMBL5403373 | 0.85 | ABCB1 (0.43) | TRPV1HTT | |
| SCHEMBL4930701 | 0.84 | TRPV1 (0.41) | TRPV1MAPK1ALDH1A1NPSR1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO.,LTD. | 2008-03-13 | — | — | US | disclosed |
| US-7300917-B2 | Remedy for chronic disease | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | POLB 527/4885TRPV1 1916/4885MAPK1 1369/4885 |
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | EDNRA, EDNRB, LPAR2 | POLB 3551/4885TRPV1 2000/4885MAPK1 3268/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | POLB 3551/4885TRPV1 2000/4885MAPK1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.